BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,949 | -17.2% | 175,534 | -0.7% | 0.03% | -9.4% |
| Q2 2023 | $14,434 | +1.7% | 176,817 | -7.5% | 0.03% | -3.0% |
| Q1 2023 | $14,187 | -11.3% | 191,219 | -0.9% | 0.03% | -15.4% |
| Q4 2022 | $15,991 | -99.9% | 192,940 | +299.9% | 0.04% | +8.3% |
| Q3 2022 | $13,703,000 | -18.1% | 48,249 | 0.0% | 0.04% | -12.2% |
| Q2 2022 | $16,725,000 | -20.0% | 48,249 | -0.0% | 0.04% | -4.7% |
| Q1 2022 | $20,895,000 | -13.8% | 48,252 | +3.0% | 0.04% | -8.5% |
| Q4 2021 | $24,239,000 | +7.8% | 46,853 | +1.0% | 0.05% | 0.0% |
| Q3 2021 | $22,483,000 | +11.7% | 46,397 | +3.8% | 0.05% | +11.9% |
| Q2 2021 | $20,131,000 | +10.5% | 44,709 | -6.3% | 0.04% | +7.7% |
| Q1 2021 | $18,221,000 | +11.2% | 47,709 | -7.6% | 0.04% | +8.3% |
| Q4 2020 | $16,388,000 | +27.4% | 51,609 | -0.6% | 0.04% | +16.1% |
| Q3 2020 | $12,859,000 | -16.5% | 51,909 | -11.0% | 0.03% | -20.5% |
| Q2 2020 | $15,398,000 | +39.3% | 58,309 | 0.0% | 0.04% | +18.2% |
| Q1 2020 | $11,057,000 | -16.2% | 58,309 | -3.0% | 0.03% | +6.5% |
| Q4 2019 | $13,195,000 | +11.3% | 60,109 | -0.8% | 0.03% | +3.3% |
| Q3 2019 | $11,859,000 | -6.5% | 60,609 | -0.3% | 0.03% | -6.2% |
| Q2 2019 | $12,678,000 | +0.9% | 60,809 | -3.9% | 0.03% | 0.0% |
| Q1 2019 | $12,567,000 | +37.0% | 63,296 | -0.2% | 0.03% | +23.1% |
| Q4 2018 | $9,175,000 | -29.1% | 63,396 | 0.0% | 0.03% | -13.3% |
| Q3 2018 | $12,940,000 | +38.0% | 63,396 | 0.0% | 0.03% | +30.4% |
| Q2 2018 | $9,379,000 | -7.3% | 63,396 | -5.4% | 0.02% | -8.0% |
| Q1 2018 | $10,119,000 | +15.4% | 66,996 | -1.0% | 0.02% | +19.0% |
| Q4 2017 | $8,770,000 | +7.2% | 67,696 | 0.0% | 0.02% | +5.0% |
| Q3 2017 | $8,184,000 | +2.9% | 67,696 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $7,954,000 | +9.8% | 67,696 | -5.0% | 0.02% | +11.1% |
| Q1 2017 | $7,247,000 | -1.1% | 71,296 | 0.0% | 0.02% | -5.3% |
| Q4 2016 | $7,331,000 | -6.1% | 71,296 | 0.0% | 0.02% | -9.5% |
| Q3 2016 | $7,807,000 | +2.3% | 71,296 | +5.3% | 0.02% | +5.0% |
| Q2 2016 | $7,634,000 | +19.3% | 67,696 | 0.0% | 0.02% | +17.6% |
| Q1 2016 | $6,399,000 | +5.0% | 67,696 | 0.0% | 0.02% | +6.2% |
| Q4 2015 | $6,093,000 | -2.7% | 67,696 | 0.0% | 0.02% | -11.1% |
| Q3 2015 | $6,259,000 | -6.1% | 67,696 | 0.0% | 0.02% | +5.9% |
| Q2 2015 | $6,666,000 | -1.8% | 67,696 | 0.0% | 0.02% | 0.0% |
| Q1 2015 | $6,789,000 | -45.7% | 67,696 | -50.0% | 0.02% | +6.2% |
| Q4 2014 | $12,510,000 | – | 135,392 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |